Scholarlink

<p>For patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) driver mutations, EGFR-tyrosine kinase inhibitors (TKIs) are the standard treatment, yet the development of acquired resistance is inevitable. There is currently no standard treatment for first-line TKI-resistant NSCLC patients. In recent years, although immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced NSCLC without driver gene mutations, the clinical efficacy of these agents in patients with advanced NSCLC harboring EGFR mutations remains limited. Whether ICIs are suitable for patients with EGFR-mutated advanced NSCLC still warrants further investigation.</p><p>This review summarizes several clinically utilized ICIs, presents clinical evidence regarding the efficacy of immunotherapy in patients with EGFR-mutated advanced NSCLC, and identifies EGFR-mutated subpopulations that may benefit from ICI treatment. On this basis, we explored more effective therapeutic strategies to extend the benefits of immunotherapy to a larger cohort of patients with EGFR-mutated NSCLC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunotherapy in EGFR-mutant non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Liwen Wang,
  • Xinghong Xian,
  • Hua Ke,
  • Ke Wang

摘要

For patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) driver mutations, EGFR-tyrosine kinase inhibitors (TKIs) are the standard treatment, yet the development of acquired resistance is inevitable. There is currently no standard treatment for first-line TKI-resistant NSCLC patients. In recent years, although immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced NSCLC without driver gene mutations, the clinical efficacy of these agents in patients with advanced NSCLC harboring EGFR mutations remains limited. Whether ICIs are suitable for patients with EGFR-mutated advanced NSCLC still warrants further investigation.

This review summarizes several clinically utilized ICIs, presents clinical evidence regarding the efficacy of immunotherapy in patients with EGFR-mutated advanced NSCLC, and identifies EGFR-mutated subpopulations that may benefit from ICI treatment. On this basis, we explored more effective therapeutic strategies to extend the benefits of immunotherapy to a larger cohort of patients with EGFR-mutated NSCLC.